Skip to main content
. Author manuscript; available in PMC: 2021 May 10.
Published in final edited form as: Clin Sci (Lond). 2021 Apr 30;135(8):1053–1063. doi: 10.1042/CS20201498

Figure 5. THS exposure significantly affects leukemia and lymphoma development.

Figure 5.

A. Cancer-free survival curves of bone marrow recipient mice which received bone marrow from control (blue; n=30) and THS (green; n=32) exposed donor mice. P value was obtained by Log-Rank Mantel-Cox test.

B. Cumulative incidence functions for competing risk of solid tumor development (dashed lines; n=5 for control, n=9 for THS) with leukemia/lymphoma (solid lines; n=24 for control, n=17 for THS) as first observed event (control mice indicated in blue and THS mice in green). Competing risk analysis: Control vs. THS p=0.02 for leukemia/lymphoma, p=0.13 for solid tumors.

C. Correlation between the percentage of transplanted B cells and tumor latency of non-leukemia-lymphoma cancers in the combined control and THS cohorts. Control mice indicated in blue and THS mice in green. P-value was obtained using Spearman Correlation.